{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:08:50Z","timestamp":1775646530434,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T00:00:00Z","timestamp":1587859200000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"IEM GmbH Stolberg","award":["provision of the ABPM devices and of the patient m"],"award-info":[{"award-number":["provision of the ABPM devices and of the patient m"]}]},{"name":"German working group of paediatric cardiologists in private practice","award":["governmental registration fees and office supplies"],"award-info":[{"award-number":["governmental registration fees and office supplies"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gen. Psychiatry"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Attention\u2010deficit\/hyperactivity disorder (ADHD) is a common behavioural disorder in childhood. The psychostimulant methylphenidate hydrochloride (MPH) is one of the major pharmacological options for ADHD. MPH is known to result, on average, in a small increase in arterial blood pressure (BP). However, there are few clinical data regarding the\n                      <jats:italic>individual<\/jats:italic>\n                      influences of MPH on BP among children and adolescents with ADHD. According to the European Union\u2010wide standardised patient information sheet for MPH, BP changes &gt;10\u2009mm Hg compared with baseline values are \u2018common\u2019 (ie, \u22651%\u2009to &lt;10%) in children and adolescents with ADHD during MPH therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate the frequency and individual severity of BP changes in children and adolescents with ADHD during the first 6\u00a0months of new MPH therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, 44 (77% male) children and adolescents (mean age (SD) 9.13 (1.86) years) with a diagnosis of ADHD according to the International Classification of Diseases, tenth revision, underwent ambulatory BP monitoring before and during the first 6\u2009months of routine MPH therapy. Exclusion criteria were pre\u2010existing MPH therapy and other medications that potentially influence BP or interfere with MPH. The non\u2010interventional study was conducted prospectively at 10 paediatric cardiology centres in Germany and Austria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After beginning MPH therapy, 34% of participants (99% CI 15.52% to 52.66%) had BP increases\/decreases &gt;10\u2009mm Hg. The mean changes in systolic BP and diastolic BP were 0.87\u2009mm Hg (95%\u2009CI \u20101.75\u2009mm Hg to 3.48\u2009mm Hg) and 1.96\u2009mm Hg (95%\u2009CI 0.21\u2009mm Hg to 3.7\u2009mm Hg), respectively. The proportion of participants with initial prehypertension\/hypertension was 54.55%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our sample with a high baseline rate of prehypertension\/hypertension, BP changes &gt;10\u2009mm Hg during MPH therapy were more frequent than those indicated by the patient information sheet. Moreover, individual BP changes, including increases and decreases &gt;10\u2009mm Hg, resulted in a small average BP increase in the sample, thus reflecting neither the severity nor the direction of individual BP changes. Therefore, the frequency and, due to the common use of the arithmetic mean, the individual severity of BP changes during MPH therapy may be underestimated. Further studies without averaging and with larger samples including patients in primary care settings are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gpsych-2020-100193","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T04:39:30Z","timestamp":1587962370000},"update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Frequency and individual severity of arterial blood pressure changes in children and adolescents with attention\u2010deficit\/hyperactivity disorder treated with methylphenidate hydrochloride: a prospective non\u2010interventional study"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6814-2633","authenticated-orcid":false,"given":"Dorothee","family":"Busold\u2010Hagenbeck","sequence":"first","affiliation":[{"name":"University Medical Centre G\u00f6ttingen G\u00f6ttingen Lower Saxony Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Elmenhorst","sequence":"additional","affiliation":[{"name":"German Heart Centre Munich Munich Bavaria Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Irtel von Brenndorff","sequence":"additional","affiliation":[{"name":"Medical Practice for Paediatric Cardiology Baden\u2010Baden Baden\u2010W\u00fcrttemberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Hilgers","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics University Medical Centre G\u00f6ttingen G\u00f6ttingen Lower Saxony Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hulpke\u2010Wette","sequence":"additional","affiliation":[{"name":"Medical Practice for Paediatric Cardiology G\u00f6ttingen Lower Saxony Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,4,26]]},"reference":[{"key":"e_1_2_15_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12381"},{"key":"e_1_2_15_3_2","unstructured":"DGKJP (Dt. Ges. f. Kinder\u2010 und Jugendpsychiatrie und Psychosomatik und Psychotherapie e. V.).Langfassung der interdisziplin\u00e4ren evidenz\u2010 und konsensbasierten (S3) Leitlinie \u201cAufmerksamkeitsdefizit\u2010\/Hyperaktivit\u00e4tsst\u00f6rung (ADHS) im Kindes\u2010 Jugend\u2010 und Erwachsenenalter.\u201d 2017. Available:https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/028\u2010045.html[Accessed 5\u00a0Jun 2018]."},{"key":"e_1_2_15_4_2","unstructured":"Fachinformationsverzeichnis Deutschland.Methylphenidat\u2010Hydrochlorid 2018. Available:http:\/\/www.fachinfo.de\/suche\/stoff\/077000[Accessed 29\u00a0Jun 2019]."},{"key":"e_1_2_15_5_2","unstructured":"Kommission der Europ\u00e4ischen Gemeinschaften.Entscheidung der Europ\u00e4ischen Kommission vom 27.5.2009 \u00fcber die Zulassung von Humanarzneimitteln mit dem Wirkstoff \u201cMethylphenidat\u201d im Rahmen von Artikel 31 der Richtlinie 2001\/83\/EG des Europ\u00e4ischen Parlaments und des Rates. Anhang II 2009. Available:https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/Risikoinformationen\/RisikoBewVerf\/m\u2010r\/methylphenidat_ke_annex.pdf?__blob=publicationFile&v=3[Accessed 17\u00a0Jan 2017]."},{"key":"e_1_2_15_6_2","unstructured":"BfArM (Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte).Abwehr von Arzneimittelrisiken. Stufe II: Methylphenidat\u2010haltige Arzneimittel. Informationsbrief des BfArM vom 04.03.2008 \u00fcber die Einleitung eines nationalen Stufenplanverfahrens 2008. Available:http:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/Risikoinformationen\/RisikoBewVerf\/m\u2010r\/methylphenidat_schreiben.pdf?__blob=publicationFile&v=3[Accessed 17\u00a0Jan 2017]."},{"key":"e_1_2_15_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32832f4f6b"},{"key":"e_1_2_15_8_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A367"},{"key":"e_1_2_15_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2009.02.008"},{"key":"e_1_2_15_10_2","doi-asserted-by":"publisher","DOI":"10.17269\/s41997-018-0067-0"},{"key":"e_1_2_15_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0042"},{"key":"e_1_2_15_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-005-2051-1"},{"key":"e_1_2_15_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.11.037"},{"key":"e_1_2_15_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000173291.28688.e7"},{"key":"e_1_2_15_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200207000-00008"},{"key":"e_1_2_15_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000106223.36344.df"},{"key":"e_1_2_15_17_2","first-page":"1","volume-title":"Duale Reihe P\u00e4diatrie","author":"Neuh\u00e4user G","year":"2002"},{"key":"e_1_2_15_18_2","unstructured":"DIMDI (Deutsches Institut f\u00fcr Medizinische Dokumentation und Information).ICD\u201010\u2010GM Version 2017 Systematisches Verzeichnis. Stand 23.09.2016 [Internet]. K\u00f6ln 2017. Available:http:\/\/www.dimdi.de\/dynamic\/de\/klassi\/downloadcenter\/icd\u201010\u2010gm\/version2017\/systematik\/"},{"key":"e_1_2_15_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/MBP.0b013e328338892f"},{"key":"e_1_2_15_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/MBP.0b013e328339be38"},{"key":"e_1_2_15_21_2","unstructured":"DGPK (Deutsche Gesellschaft f\u00fcr P\u00e4diatrische Kardiologie).Arterielle Hypertonie. S2k Leitlinie P\u00e4diatrische Kardiologie P\u00e4diatrische Nephrologie und P\u00e4diatrie. Aktualisierte version vom 30.06.2015 2015. Available:http:\/\/www.kinderkardiologie.org\/leitlinien\/[Accessed 26\u00a0Jun 2019]."},{"key":"e_1_2_15_22_2","volume-title":"The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents","author":"NHBPEP (National High Blood Pressure Education Program Working Group on Children and Adolescents)","year":"2005"},{"key":"e_1_2_15_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-011-1964-0"},{"key":"e_1_2_15_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780111005"},{"key":"e_1_2_15_25_2","volume-title":"Referenzperzentile f\u00fcr anthropometrische Ma\u00dfzahlen und Blutdruck AUS Der studie Zur Gesundheit von Kindern und Jugendlichen in Deutschland (KIGGS)","author":"Neuhauser H","year":"2013"},{"key":"e_1_2_15_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15081789"},{"key":"e_1_2_15_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d643"},{"key":"e_1_2_15_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001039"},{"key":"e_1_2_15_29_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.84.4.633"},{"key":"e_1_2_15_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-012-2215-8"},{"key":"e_1_2_15_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0141"},{"key":"e_1_2_15_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2550"}],"container-title":["General Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1136\/gpsych-2020-100193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1136\/gpsych-2020-100193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1136\/gpsych-2020-100193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T10:35:25Z","timestamp":1775644525000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1136\/gpsych-2020-100193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/gpsych-2020-100193"],"URL":"https:\/\/doi.org\/10.1136\/gpsych-2020-100193","archive":["Portico"],"relation":{},"ISSN":["2096-5923","2517-729X"],"issn-type":[{"value":"2096-5923","type":"print"},{"value":"2517-729X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]},"article-number":"e100193"}}